Ifosfamide or trofosfamide in patients with intraocular lymphoma

@article{Jahnke2008IfosfamideOT,
  title={Ifosfamide or trofosfamide in patients with intraocular lymphoma},
  author={Kristoph Jahnke and Eckhard Thiel and Nikolaos E. Bechrakis and Gregor D. Willerding and Dale Kraemer and Lars Fischer and Agnieszka Korfel},
  journal={Journal of Neuro-Oncology},
  year={2008},
  volume={93},
  pages={213-217}
}
We evaluated response, progression-free survival (PFS), overall survival (OS), relapse patterns and long-term toxicity of intraocular lymphoma (IOL) patients treated with ifosfamide (IFO) or trofosfamide (TRO). In a prospective single center study, IFO or TRO were given to 10 patients with IOL. The median patient age was 73 (range 46–83) years. Six patients were pretreated with up to four treatment regimens for ocular or cerebral lymphoma, and four were therapy-naive. All patients responded… 

Primary intraocular lymphoma: treatment outcomes with ocular radiation therapy alone

Ocular RT alone resulted in excellent ocular control of PIOL, and relapses were effectively salvaged and two-year freedom-from-relapse was not different between the groups.

Treatment options for central nervous system lymphomas in immunocompetent patients

An overview of the current status of CNS lymphoma treatment is presented and future directions in the management of PCNSL and CNS relapse of systemic lymphoma may include treatment stratification according to patient age and clinical and biological prognostic factors.

Clinical Review: Treatment of Vitreoretinal Lymphoma

This review summarizes the present knowledge on vitreoretinal lymphoma therapy, with an eye to future molecular approaches.

DLBCL, primary and secondary central nervous system involvement, treatment and prophylaxis

This study retrospectively analyses patients who treated as first line with Bonn/Bonn-like treatment, with BBBD treatment followed by high-dose treatment/autologous stem cell transplantation in firstor second-line or those treated with primary RCHOP or its derivatives with or without concurrent CNS-targeted treatment.

New approaches in primary central nervous system lymphoma.

The goal in this review is to update principles of diagnosis and management as well as data regarding the molecular pathogenesis of PCNSL, information that may constitute a basis for development of more effective therapies required to make additional advances in this phenotype of aggressive NHL.

Case-based review: primary central nervous system lymphoma.

Most patients are now initially treated with high-dose-methotrexate-based chemotherapy alone, as the addition of whole-brain radiotherapy at standard doses has not been shown to increase survival and does increase the risk of neurological toxicity.

Primary vitreoretinal lymphoma: prevalence, impact, and management challenges

Local therapies, including intravitreal injections of methotrexate and/or rituximab and low-dose radiotherapy to the eye, have been shown to be extremely effective in controlling intraocular lymphoma.

Clinical Features, Diagnosis, Management and Prognosis of Primary Intraocular Lymphoma

Overall, intravitreal injection of chemotherapy drug plus systemic chemotherapy (IV+CT) could achieve satisfactory prognosis, the combination of local radiotherapy (RT) could further decrease the recurrent and death rate.

Present and future treatment options for primary CNS lymphoma

This review focuses on either the actual pharmaco-therapeutic knowledge or the predictable future developments for the immunocompetent population (the vast majority of patients today) as well as management of elderly patients and of relapsed disease.

Primary central nervous system lymphoma.

References

SHOWING 1-10 OF 30 REFERENCES

Pharmacokinetics and efficacy of ifosfamide or trofosfamide in patients with intraocular lymphoma.

  • K. JahnkeT. Wagner A. Korfel
  • Medicine
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2005
IOL patients evidence aqueous penetration of 4-OH metabolites after intravenous administration of IFO, and IFO and TRO are active in IOL.

Ifosfamide in Hematological Malignancies of Adults

Ifosfamide is an alkylating agent with a broad spectrum of activity in solid tumors and hematological malignancies and its use in the treatment of lymphomas and Hodgkin’s disease is illustrated.

Intraocular lymphoma 2000–2005: results of a retrospective multicentre trial

The prognosis of PIOL is similar to that of PCNSL without ocular involvement, and the high response rate to monotherapy with IFO and TRO is promising, which possibly prolongs PFS as compared with local management of (P)IOL.

Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07.

  • T. BatchelorK. Carson R. Priet
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2003
The results indicate that high-dose methotrexate is associated with modest toxicity and a radiographic response proportion comparable to more toxic regimens.

Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy.

Primary chemotherapy based on high-dose MTX and ARA-C is highly efficient in PCNSL and response rate and response duration are comparable to the response rates and durations reported after combined radiotherapy and chemotherapy.

Relevance of intraocular involvement in the management of primary central nervous system lymphomas.

  • A. FerreriJ. Blay F. Cavalli
  • Medicine
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2002
Chemotherapy combined with ocular irradiation resulted in better control of ocular disease, which seems to be associated with survival, and the use of chemotherapy alone in phase II trials should be critically reconsidered in PCNSL patients withOcular disease.

Primary intraocular lymphoma (PIOL): An International Primary CNS Lymphoma Collaborative group report.

  • S. GrimmJ. Pulido L. Abrey
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2006
To minimize toxicity, the best initial therapy should be limited to intraocular chemotherapy or focal radiotherapy, and treatment type did not affect sites of relapse, PFS or OS in patients with PIOL.

Cyclophosphamide and ifosfamide metabolites in the cerebrospinal fluid of children.

It is demonstrated that IF enters the CSF to a greater extent than CP in children, and the ability of both IF and CP and their metabolites to cross the blood-brain barrier may be reduced by dexamethasone.

Ocular presentation of primary central nervous system lymphoma: diagnosis and treatment

Patients whose ocular disease was identified and treated before CNS progression had a significantly improved survival, and treatment with chemotherapy and/or ocular radiotherapy failed to prevent CNS progression.